Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026

Liquidia Corporation (LQDA)

Nasdaq Health Care Pharmaceuticals S&P SmallCap 600
$44.40
-0.09 (-0.20%)
Close of Nov 06, 2026 · end-of-day data
Next earnings date
Tue, Nov 10, 2026
Before market open · quarter ending Sep/2026
Consensus EPS estimate
$0.77
2 analysts · year-ago EPS $-0.04
Trailing 12-month EPS
$1.39
Diluted, last four reported quarters

Earnings surprise history

reported EPS vs consensus
ReportedQuarterEPS estimateReported EPSSurprise
Nov 02, 2026Sep/2026$0.77$-0.04—

Our record of LQDA's reports since we began tracking; it grows each quarter.

Latest results, in brief

All LQDA 8-K briefs →
Aug 12, 6:45 AM ET

Liquidia Q2 2026 net income $74.7 million on $170.4 million YUTREPIA net product sales

Positive earnings Written later 2.028.01

Liquidia reported second quarter 2026 results for the period ended June 30, 2026, with total revenue of $171.7 million and net income of $74.7 million, or $0.74 per diluted share, compared with a net loss of $41.6 million a year earlier. The company also filed an updated corporate presentation for healthcare conferences and analyst meetings.

  • Net product sales of YUTREPIA were $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026
  • Net income was $74.7 million, or $0.74 per diluted share, versus a net loss of $41.6 million, or $0.49 per share, in the second quarter of 2025
  • Cash and cash equivalents were $284.2 million as of June 30, 2026, compared with $190.7 million as of December 31, 2025
  • Research and development expenses rose to $17.2 million and SG&A expenses rose to $57.4 million for the quarter
Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.

Quarterly results

Full financial statements →
Quarter endedRevenueYoYEPS (diluted)YoYNet incomeNet margin
Jun 2026$171.68M+1842.7% $0.74— $74.72M43.5%
Mar 2026$132.87M+4158.5% $0.52— $52.86M39.8%
Dec 2025$92.02M+3054.6% $0.17— $14.55M15.8%
Sep 2025$54.34M+1121.7% $-0.04— -$3.53M-6.5%
Jun 2025$8.84M+141.5% $-0.49— -$41.58M-470.5%
Mar 2025$3.12M+5.0% $-0.45— -$38.37M-1229.7%
Dec 2024$2.92M-35.6% $-0.45— -$38.51M-1320.2%
Sep 2024$4.45M+20.9% $-0.40— -$31.03M-697.6%

From Liquidia Corporation's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.

Annual results

Fiscal yearRevenueGrowthEPS (diluted)GrowthNet margin
FY2025$158.32M+1031.2% $-0.80—-43.5%
FY2024$14.00M-20.0% $-1.63—-916.6%
FY2023$17.49M+9.7% $-1.21—-448.9%
FY2022$15.94M+24.0% $-0.67—-257.4%
FY2021$12.85M+1637.8% $-0.70—-269.0%

Frequently asked questions

When is Liquidia's next earnings date?

Liquidia (LQDA) is scheduled to report on Tuesday, November 10, 2026 before the market opens. Analysts expect EPS of $0.77.

What did Liquidia earn last quarter?

For the quarter ended Jun 2026, Liquidia reported diluted EPS of $0.74 on revenue of $171.68M (+1842.7%).

Where do these numbers come from?

Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.

Not investment advice. Figures can be restated by the company in later filings.